Safety, tolerability, and outcomes of psilocybin in veterans with spical cord injury

The Defense Health Agency (DHA) awarded The Bronx Veterans Medical Research Foundation, Inc. (BVMRF) a Project Grant totaling $1,499,912 under the Military Medical Research and Development program (CFDA 12.420), effective June 1, 2025, through May 31, 2028. The primary deliverable under this award is a clinical research study investigating the safety, tolerability, and outcomes of psilocybin treatment in veterans with spinal cord injury. This research project represents the DHA's commitment to exploring innovative therapeutic approaches for military-relevant medical conditions and contributes to the broader program objective of transforming healthcare outcomes for service members and veterans through advanced biomedical research.

BVMRF, a non-profit research foundation specializing in veterans' healthcare research, will conduct this hypothesis-driven clinical investigation at its performance location in the Bronx, New York. The three-year project aligns with the Military Medical Research and Development program's emphasis on applied and advanced research addressing critical health challenges affecting the veteran population. As a recognized research partner of the DHA with established expertise in conducting specialized medical investigations, BVMRF will leverage its institutional capabilities and collaborative networks to complete this study within the performance period and deliver findings intended to inform clinical practice and therapeutic options for veterans with spinal cord injuries.